Tawada H, Natsugari H, Ishikawa E, Sugiyama Y, Ikeda H, Meguro K
Pharmaceutical Research Laboratories II, Takeda Chemical Industries, Ltd., Osaka, Japan.
Chem Pharm Bull (Tokyo). 1995 Apr;43(4):616-25. doi: 10.1248/cpb.43.616.
Novel 3-ureido derivatives of 4-phenylcoumarin and 4-phenyl-2-quinolone were synthesized and evaluated for acyl-CoA: cholesterol acyltransferase (ACAT)-inhibitory activity. These derivatives inhibited rat intestinal ACAT with IC50 values at the 10(-8) to 10(-9) M level and were found to normalize plasma cholesterol levels in cholesterol-fed rats when administered as dietary admixtures.
合成了新型的4-苯基香豆素和4-苯基-2-喹诺酮的3-脲基衍生物,并对其酰基辅酶A:胆固醇酰基转移酶(ACAT)抑制活性进行了评估。这些衍生物以10(-8)至10(-9)M的IC50值抑制大鼠肠道ACAT,并且当作为膳食添加剂给药时,发现其可使胆固醇喂养大鼠的血浆胆固醇水平正常化。